Meet The Team
Tom Westling
Previously, as co-founder of Rotation Medical, Tom successfully led efforts to revolutionize bioinductive tissue implant technology which ultimately was purchased by Smith & Nephew in 2017 for $210 million and rebranded as Regeneten. It was during this experience that he witnessed the biggest unmet need in soft tissue repair is to mitigate retears which led to the formation of Integrity Orthopaedics.
The Rotation Medical experience is not the first world class innovation in Tom’s history. He also has led efforts for two other highly impactful medical devices: Renewal, the world’s first heart failure device; and Emblem, the world’s first subcutaneous implantable cardioverter defibrillator.
He has more than 35 years of experience in R&D, Operations, Quality, Clinical, Regulatory, and Marketing in Corporate, Manufacturing, and Start-up environments within the medical device industry.
Ryan Majkrzak
Ryan Majkrzak joined Integrity Orthopaedics in 2023 as the Chief Operating Officer. He came to Integrity from Boston Scientific Corporation, where he held VP leadership roles in US Cardiology Sales PMO, Commercial Portfolio Management for Structural Heart, and leading the Mitral & Tricuspid franchise.
Previous to this, Ryan led the Interventional Cardiology Business Development team, and was responsible for a number of strategic acquisitions and venture investments.
Ryan joined Boston Scientific in 2012 through the acquisition of San Clemente, CA based Cameron Health and its subcutaneous implantable defibrillator (S-ICD) technology. At Cameron, Ryan held senior leadership positions as VP of Quality and Director of Manufacturing. He began his career at Guidant Corporation, working in roles of increasing responsibility in R&D, Manufacturing and Supply Chain in Clonmel, Ireland and St. Paul, MN.
Josh Lee
Josh Lee joined Integrity Orthopaedics in the beginning of 2024 as the Vice President of Sales. He came to Integrity from Treace Medical Concepts, Inc., where he was a Regional Vice President of Sales. Treace Medical Concepts, Inc. is the market leader for the surgical management of bunions and related midfoot deformities. Josh was an integral part of building and leading the sales organization through their IPO in 2021.
Previous to this, Josh led sales management teams at Stryker Orthopaedics extending from joint replacement, trauma, and sports medicine markets from 2006–2017. Josh achieved multiple World-Class Sales Leadership awards and contributed to making these markets the fastest growing within Stryker during his tenure.
David Crompton
David Crompton co-founded Integrity Orthopaedics after successfully serving as Chief Patent Counsel for Rotation Medical from 2009-2017 including the development of a strategic patent portfolio of over 50 patents in U.S. Throughout his career, David has provided intellectual property consultancy to a variety of other medical device companies. His extensive experience in patent prosecution in medical device technologies makes him an integral part of the innovation team at Integrity Orthopaedics.
Patrick Connor, MD, FAOA
Dr. Patrick Connor is a distinguished sports medicine specialist affiliated with OrthoCarolina in Charlotte, North Carolina. He serves as a Professor and Chief of Sports Medicine & Shoulder/Elbow within the Department of Orthopaedic Surgery at Atrium Health in Charlotte, NC.
With a wealth of experience and expertise in the field, Dr. Connor has earned the honor of being the Past President of the NFL Physicians Society, showcasing his commitment to advancing sports medicine at the highest levels.
In addition to his clinical and leadership roles, Dr. Connor is a prolific contributor to the field of orthopaedics with over 100 research publications and book chapters. His work has garnered recognition, leading him to be a valuable member of the Editorial Review Board for renowned orthopaedic journals such as JBJS (Journal of Bone and Joint Surgery), JSES (Journal of Shoulder and Elbow Surgery), and AJSM (American Journal of Sports Medicine).
This extensive involvement underscores his dedication to advancing the understanding and practice of sports medicine for improved patient outcomes.
Howard Harris, MD
Dr. Howard Harris is a highly accomplished Orthopaedic Surgeon and Founding Partner at Texas Orthopedic Specialists, PLLC, based in Dallas/Fort Worth, TX. With a notable presence in the field, Dr. Harris brings extensive experience and expertise to the medical community.
With over 13 years of dedicated research experience in clinical trials, Dr. Harris has made significant contributions to the advancement of the orthopaedic industry. His focus extends beyond clinical trials to encompass surgical skills education, prototype evaluation, surgical technique development, as well as implant and instrument design, collaborating with leading orthopaedic manufacturers, including Smith & Nephew and FX Solutions.
In addition to his clinical and research endeavors, Dr. Harris is on the Board of Directors for THSL Surgical Hospital, Baylor Trophy Club Surgical Hospital and Bear Creek Surgery Center. He is also a Fellow of the AAOS and a member of the ASES and AOSSM. His multifaceted contributions to the field underscore his dedication to enhancing patient care and advancing soft-tissue repair.
Marc Labbe, MD
Dr. Marc Labbe is a distinguished Orthopaedic Surgeon affiliated with the Houston Methodist Hospital in Houston, TX. With a focus on Sports Medicine, Dr. Labbe has established himself as a prominent figure in the field, contributing significantly to both patient care and industry advancement.
Dr. Labbe has played a crucial role in product and surgical technique development, collaborating with leading orthopedic companies to enhance the field’s standards. His expertise extends beyond clinical practice, as he has served as the President of the Medical Staff at Houston Methodist, The Woodlands Hospital, demonstrating his leadership and commitment to delivering high-quality healthcare.
Based in Houston, TX, Dr. Marc Labbe’s multifaceted contributions to orthopedics reflect his dedication to staying at the forefront of the field, providing exceptional patient care, and actively participating in the development of innovative surgical techniques and orthopedic products.
Michael DeMane
Michael DeMane served as the CEO at Nevro from 2011 to 2016, guiding the company from a startup with minimal revenue to a key global player in the spinal cord stimulation market. During his tenure, Michael focused on building the business’s mechanics and culture, leading to the successful completion of two venture funding rounds totaling $106 million, a $145 million IPO and a subsequent public follow-on offering, also upsized to $260 million.
Trained as an engineer, Michael boasts a consistent track record of success in leadership roles within both large and mid-size global med-tech organizations over the past 35 years. His executive positions have spanned across the United States, Europe, and Australasia.
Before joining Nevro, Michael held various roles at Medtronic, Inc., including Chief Operating Officer, Senior Vice President and President of Europe, Canada, Latin America, and Emerging Markets, as well as Senior Vice President and President of Spinal, ENT, and Navigation. In each of these roles, he served on Medtronic’s Executive Committee.
Prior to his time at Medtronic, Michael served as Managing Director, Australasia for Smith & Nephew Pty. Ltd.
In addition to his executive roles, Michael serves on the board for several firms in the medtech sector.
John Penshorn
John Penshorn’s impressive career includes over two decades of service on the UnitedHealth Group Operating Committee, where he helped shape the company’s trajectory. In his capacity within the committee, John spearheaded the Investor Relations function and made substantial contributions to corporate strategy, communications, leadership development, and innovation. John previously served as an equity analyst for Piper Jaffray and received an MBA from the Carlson School at the University of Minnesota, after practicing as a CPA (currently inactive license).
Beyond his impactful corporate journey, John extends his influence as an angel investor and serves on the boards of multiple companies. His diverse involvement reflects a keen interest in fostering innovation, strategic leadership, and the growth of enterprises.
Tom Schnettler
Tom Schnettler is vice chairman of Piper Sandler Companies, president of Piper Sandler Investment Group, Inc. and a managing director in the merchant banking group. In his merchant banking role, Tom serves as a managing director of PSC Capital Partners LLC, the registered investment adviser to the Piper Sandler merchant banking private funds. Tom also served as president and chief operating officer of Piper Sandler from 2008 to 2011, and as chief financial officer between 2006 and 2008. Prior to that, he served as head of the Piper Sandler corporate and institutional services business beginning in 2002, and as head/co-head of investment banking beginning in 2000. From 1989 to 2000, he co-founded and led the healthcare investment banking group. Tom joined the Piper Sandler investment banking group in 1986.
Tom currently serves on the board of Akoya Biosciences, Inc. (NASDAQ: AKYA), Paragon 28, Inc. (NYSE: FNA), Elligo Health Research, Inc. and Moxe Health Corporation.
Tom graduated from Saint John’s University in Collegeville, Minnesota and holds a juris doctorate from Harvard Law School.
